StreetInsider.com News Articles

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate (ORR) and duration of response (DOR):

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Thu, 27 Aug 2026 10:15:00 -0400

CS2009 Achieved Key Clinical Validations for Efficacy and Safety

Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)

At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: